Zosano Pharma (ZSAN) Getting Positive Media Coverage, Report Shows

News articles about Zosano Pharma (NASDAQ:ZSAN) have been trending positive recently, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Zosano Pharma earned a media sentiment score of 0.32 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.9916760903204 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:

NASDAQ:ZSAN traded down $0.02 during midday trading on Monday, hitting $5.02. 1,019,777 shares of the company were exchanged, compared to its average volume of 1,276,631. The firm has a market capitalization of $9.94, a P/E ratio of -0.30 and a beta of 1.92. Zosano Pharma has a fifty-two week low of $3.61 and a fifty-two week high of $38.60.

Zosano Pharma (NASDAQ:ZSAN) last posted its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($3.80) EPS for the quarter, beating analysts’ consensus estimates of ($4.80) by $1.00. research analysts anticipate that Zosano Pharma will post -18 EPS for the current fiscal year.

Separately, ValuEngine lowered shares of Zosano Pharma from a “sell” rating to a “strong sell” rating in a report on Tuesday, February 27th.

In related news, major shareholder Amzak Capital Management, Llc sold 88,281 shares of the business’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $8.40, for a total transaction of $741,560.40. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 2.83% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: “Zosano Pharma (ZSAN) Getting Positive Media Coverage, Report Shows” was originally posted by BBNS and is owned by of BBNS. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://baseballnewssource.com/2018/04/03/zosano-pharma-zsan-earns-media-sentiment-rating-of-0-32/2009687.html.

About Zosano Pharma

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.

Insider Buying and Selling by Quarter for Zosano Pharma (NASDAQ:ZSAN)

Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Tampa Bay Starting Relievers In Place of Starters
Tampa Bay Starting Relievers In Place of Starters
Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old


Leave a Reply

 
© 2006-2018 BBNS.